echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The development of the daily hepatitis C drug portfolio SOF/DCV accelerates the clinical recovery of patients with new crown systology.

    The development of the daily hepatitis C drug portfolio SOF/DCV accelerates the clinical recovery of patients with new crown systology.

    • Last Update: 2020-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    2020.07.17 Research news: The treatment of Alzheimer's disease anti-Tau vaccine starts phase 1b/2a trial; treatment of acute myocardial heart failure after death Farxiga is FDA fast-track qualification; seven new drugs approved clinically from AstraZeneca, Bayer... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
    (click on the title, read the original text) (drug research and development) hepatitis C drug combination SOF/DCV accelerated clinical recovery of patients with new crown sepsis on the 16th, at the 23rd Virtual International AIDS Conference published a new study, antiviral drug combination sofsbuvir/daclatasvir joint standard therapy, in moderate or severe COVID-19 patients showed a recovery-related improvement, reduced hospital time.
    the launch of phase 1b/2a trial for Alzheimer's disease, The Swiss-based clinical biopharmaceutical company AC Immune SA announced that it will launch a phase 1b/2a clinical trial in its ACI-35.030 higher dose group of the Alzheimer's (AD) vaccine.
    Drug Approval for the Treatment of Heart Failure After Death of Acute Myocardial Infarction, AstraZeneca announced that Farxiga has been granted fast-track status by the FDA to reduce the risk of hospitalization or cardiovascular death for heart failure caused by acute myocardial infarction or heart attack in adult patients.
    Bayer/Mercadon heart failure new drug listing application by the FDA priority review 16, Bayer and Mercado jointly announced that the U.S. FDA has accepted the new drug application and granted its priority review eligibility for treatment after experiencing heart failure deterioration after the blood score of less than 45% of patients with chronic heart failure.
    seven new drugs approved for clinical use from AstraZeneca, Bayer... On the 17th, CDE website information showed that a number of drugs have been approved for clinical trials, including four imported new drugs.
    these products come from AstraZeneca, Bayer, Reding Pharmaceuticals, Hengrui Pharmaceuticals, Novartis and Aishi.
    the world's first new drug of sophine bio-tumor to obtain FDA rapid review channel qualification 17, Soyuan Bio announced that the United States FDA awarded its world-first new drug DB102 for the first-line treatment of glioblastoma fast review channel qualification.
    Beijing New Pharmaceuticals "Hydrochloric Acid Kaueriviron Tablets" by the United States ANDA approval number 16, Beijing New Pharmaceuticals to the FDA to declare the application for a short new drug (ANDA) of hydrochloric acid koalas has been approved.
    determined that The application for listing of the hydrochloric acid koala viron tablets and the original research Daiichi Sankyo has been listed hydrochloric acid koala saucerin equivalent.
    two products of the company obtained medical device registration certificate today, Kei Egg Biotech Co., Ltd. issued a notice that the company's holding subsidiary Changchun Blazer recently received by Jilin Province Drug Administration issued two "medical device registration certificate."
    two products are a fully automatic urine analyzer and a fully automatic biochemical analyzer.
    Jincheng Pharmaceutical injection sodium cephalosporine approved clinical 16, Jincheng Pharmaceutical announcement said that it received the holding subsidiary Guangdong Jincheng Jinjin inthere notification, it obtained the Approval issued by the State Drug Administration on the injection of cephalosporine 2.4 modified new drug "drug clinical trial approval notice", will carry out new clinical trials of adaptation.
    Five-in-one" viral immunotherapy partnered with Keytruda Mercadon in clinical research today, Oncorus announced a clinical trial cooperation agreement with Mercadon to evaluate the efficacy of Oncorus-developed viral immunotherapy ONCR-177 and anti-PD-1 therapy Keytruda to treat patients with late-stage and/or refractive skin, subcutaneous or metastatic lymph nodes.
    Benchmark Medical and Johnson Lung Cancer Center to carry out early diagnosis of lung cancer research cooperation 17, Guangzhou Benchmark Medical and Johnson Lung Cancer Center announced a multi-year cooperation in the field of early diagnosis of lung cancer to jointly promote early lung cancer detection and diagnosis research.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.